We are proudly supporting clinical trials across Australia to benefit people with cancer

Icon Cancer Foundation is dedicated to improving access to advanced treatments for cancer through the promotion of investigator initiated clinical trials.

Currently, we support the delivery of over ten clinical trials for cancer patients across Australia. These clinical trials:

  • Conduct research on the safety and effectiveness of new medications and treatment
  • Validate the use of treatments against the current standard of care
  • Study the impact on early diagnosis, cancer prevention or quality of life

Many other trials are also under development and will be available for patients in the future. Our goal is to continue to contribute to the development of new cancer treatments and techniques that will make a lasting difference.

Clinical trials supported by Icon Cancer Foundation

+ Advanced

OP-1250-001

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer (OP-1250-001)

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

LEAD-4-BCS

A feasibility study evaluating a structured telehealth Lifestyle intervention (Exercise And Diet) for early-stage Breast Cancer Survivors (LEAD-4-BCS) undergoing neo-adjuvant/ adjuvant chemotherap

Locations

Revesby

Diagnosis

Breast cancer

Opening soon
View Trial

REFOCUS RLY-4008-101

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

OP-1250-002

A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)

Locations

Wesley, Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

SHR-A1921-I-102

A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Opening soon
View Trial

BGB-24714-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

RC198-G001

A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Locations

Wesley

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ATRIUM ATG-018-001

A Phase 1, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

PXS5505-MF-101

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Locations

Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

DB-1303-O-1001

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)

Locations

South Brisbane

Diagnosis

Breast cancer, Endometrial cancer

Open for recruitment
View Trial

ADG116-1003

A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CodeBreak-101 20190135

A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BA3011-002

A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor

Locations

Central Building (Oncology)

Diagnosis

Lung cancer

Open for recruitment
View Trial

ASPEN-06 AT148006

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma

Locations

Southport

Diagnosis

Gastric / gastroesophageal cancer

Opening soon
View Trial

ASPEN 06

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Locations

Farrer Park

Diagnosis

Gastric / gastroesophageal cancer

Open for recruitment
View Trial

BRUIN MCL-321

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Locations

Wesley

Diagnosis

Lymphoma – Hodgkin’s

Open for recruitment
View Trial

Viktoria-1 CELC-G-301

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Southport

Diagnosis

Breast cancer

Open for recruitment
View Trial

Viktoria-1

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

Locations

Farrer Park

Diagnosis

Breast cancer

Open for recruitment
View Trial

UP-NEXT MER-XMT-1536-3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive Ovarian Cancer (UP-NEXT)

Locations

Chermside, Southport, Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

AFFIRM-AL NEOD001-301

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Locations

South Brisbane, Wesley

Diagnosis

Amyloidosis

Open for recruitment
View Trial

HERTHENA–Lung02

A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-Based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR Tyrosine Kinase Inhibitor (TKI) Therapy.

Locations

Mount Alvernia

Diagnosis

Lung cancer

Open for recruitment
View Trial

CONTACT-02 XL184-315

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Locations

Chermside, Wesley

Diagnosis

Prostate cancer

Open for recruitment
View Trial

VERITAC-2 C4891001

A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

SHR-2002-102

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LM108-01-101

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CAPTURE BCT1901

A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

STELLAR 303

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

KRYSTAL-12

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Locations

Farrer Park

Diagnosis

Lung cancer

Open for recruitment
View Trial

HLX10-020-SCLC302

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Locations

Wesley

Diagnosis

Lung cancer

Open for recruitment
View Trial

BGB-A317-LBL-007-201

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Locations

South Brisbane

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

AK112-101

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Locations

South Brisbane, Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours, Ovarian cancer

Open for recruitment
View Trial

RINGSIDE AL-DES-01

A Study of AL102 in Patients With Progressing Desmoid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Sarcoma

Open for recruitment
View Trial

ABSK043-101

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

BRIGHTLINE-1

A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Sarcoma

Open for recruitment
View Trial

liDERA GO42784

A study to evaluate the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.

Locations

Hobart, Wesley, Adelaide (Kurralta Park)

Diagnosis

Breast cancer

Open for recruitment
View Trial

AK127-101

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

AML M22

AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Leukaemia

Open for recruitment
View Trial

REGENERON_ R1979-ONC-1625

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma

Locations

Farrer Park

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

DESTINY-B12 D9673C00007

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Locations

Wesley

Diagnosis

Breast cancer

Open for recruitment
View Trial

ALLG NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

BGB-A317-15025-101

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

LIBERATE

Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)

Locations

Epworth Richmond, Epworth Freemasons, Geelong

Diagnosis

Prostate cancer

Open for recruitment
View Trial

CONSOLE

Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial. (CONSOLE)

Locations

Wahroonga

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

DECREASE TROG 19.06

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Locations

Epworth Richmond

Diagnosis

Prostate cancer

Open for recruitment
View Trial

DASL-HiCaP ANZUP1801

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

Locations

Gold Coast University Hospital, Wahroonga, Gold Coast Private, Southport, Adelaide (Kurralta Park), Hobart

Diagnosis

Prostate cancer

Open for recruitment
View Trial

DECRESCENDO BCT2002 BIG19-02

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Locations

Wesley, Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

DREAM3R

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Locations

South Brisbane, Wesley, Chermside

Diagnosis

Mesothelioma

Open for recruitment
View Trial

PHI-101-001

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Locations

Wesley

Diagnosis

Leukaemia

Open for recruitment
View Trial

ASPEN-04

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Head and neck cancer

Open for recruitment
View Trial

ASPEN-03

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Locations

Adelaide (Kurralta Park)

Diagnosis

Head and neck cancer

Open for recruitment
View Trial

EXPERT BCT1601

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)

Locations

Epworth Richmond

Diagnosis

Breast cancer

Open for recruitment
View Trial

ERUPT

External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)

Locations

Toowoomba

Diagnosis

Prostate cancer

Open for recruitment
View Trial

MER-XMT-1536-1

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Locations

South Brisbane

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

HyperArc Registry VAR-2019-01

HyperArc Registry Study

Locations

Canberra, Greenslopes, Gold Coast Private, Maroochydore

Diagnosis

Brain cancer

Open for recruitment
View Trial

I-MAT MASC 03.18

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Locations

Hobart

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BOREAS KRT-232-101

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Locations

South Brisbane, Wesley

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

MASTERPLAN

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (MASTERPLAN)

Locations

Gold Coast University Hospital

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

FUZOPRO SHR3162-III-305

Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Locations

Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

MRDR

Myeloma and Related Disease Registry

Locations

Wesley, South Brisbane, Chermside, Southport

Diagnosis

Multiple myeloma

Open for recruitment
View Trial

OPTIMA 11/0479

Optimal personalised treatment of early breast cancer using multiparameter analysis

Locations

Hobart, Southport

Diagnosis

Breast cancer

Opening soon
View Trial

ZN-D5-001

Phase 1 First in Human Study of ZN-d5 as a Single Agent in Non-Hodgkin Lymphoma and Acute Myeloid Leukemia

Locations

Adelaide (Kurralta Park)

Diagnosis

Diffuse large B-cell lymphoma, Leukaemia

Open for recruitment
View Trial

CK301-101

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Locations

South Brisbane, Adelaide (Windsor Gardens)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ESCALADE D8227C00001

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤65 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Locations

South Brisbane, Wesley, Chermside, Southport

Diagnosis

Lymphoma – B-cell Non Hodgkin’s

Open for recruitment
View Trial

KRYSTAL-10

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Locations

Farrer Park

Diagnosis

Colorectal cancer

Open for recruitment
View Trial

HARMONY R3767-ONC-2011

Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Locations

Hobart

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

ARTISTRY-7 ALKS 4230-007

Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Locations

Wesley

Diagnosis

Ovarian cancer

Open for recruitment
View Trial

KEYNOTE-867 MK-3475-867

Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

UNICAB ANZUP1802

Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy

Locations

Adelaide (Kurralta Park)

Diagnosis

Kidney cancer

Open for recruitment
View Trial

TUGETHER BCT2102

Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer

Locations

Hobart

Diagnosis

Breast cancer

Opening soon
View Trial

RADIANT / BAY 88-8223 / 20510

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Locations

Chermside, Wesley, South Brisbane, Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

ASCENT-04 GS-US-592-6173

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

ASCENT-03 GS-US-592-6238

Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

Locations

Hobart

Diagnosis

Breast cancer

Open for recruitment
View Trial

TREMOR

Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)

Locations

Epworth Richmond

Diagnosis

Neurological conditions

Open for recruitment
View Trial

Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)

SLN124-004

Locations

Adelaide (Windsor Gardens), Adelaide (Kurralta Park)

Diagnosis

Myeloproliferative disorders

Open for recruitment
View Trial

HBI-8000-303

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Locations

Wesley, Chermside, Southport

Diagnosis

Skin cancer – melanoma

Open for recruitment
View Trial

C-POST R2810-ONC-1788

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Locations

Southport, Adelaide (Kurralta Park)

Diagnosis

Skin cancer – non-melanoma

Open for recruitment
View Trial

BGB-900-105 AdvanTIG-105

Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors

Locations

South Brisbane, Adelaide (Windsor Gardens)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

CAPItello-280

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Locations

Adelaide (Kurralta Park)

Diagnosis

Prostate cancer

Open for recruitment
View Trial

COSTAR_213410

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung)

Locations

North Lakes, Chermside, Wesley, Southport, South Brisbane

Diagnosis

Lung cancer

Open for recruitment
View Trial

KEYVIBE-006 MK-7684A-006

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer

Locations

Hobart

Diagnosis

Lung cancer

Open for recruitment
View Trial

EVOKE-02 GS-US-576-6220

Study of Sacituzumab Govitecan-hziy Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Locations

Adelaide (Kurralta Park)

Diagnosis

Lung cancer

Open for recruitment
View Trial

STELLAR-001

Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Locations

Adelaide (Kurralta Park)

Diagnosis

Advanced solid tumours

Open for recruitment
View Trial

ASCEND CTC0304

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Locations

Wesley

Diagnosis

Pancreatic cancer

Open for recruitment
View Trial

MAGMA

The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 or 12 cycles of temozolomide after chemoradiotherapy.

Locations

Gold Coast University Hospital, North Lakes, Greenslopes, Concord

Diagnosis

Brain cancer

Open for recruitment
View Trial

ABCPro

Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.

Locations

Bowen Icon Cancer Centre

Diagnosis

Breast cancer

Open for recruitment
View Trial
There are no clinical trials currently available

Search

Quick links
Donate